Drugmaker Novartis is halting the distribution of generic Zantac, or ranitidine, while the drug is investigated for NDMA, a probable human carcinogen.

The opioid crisis is to blame for an “alarming” number of cases of infective endocarditis, according to the American Heart Association.

A study published in the Annals of Internal Medicine Sept. 17 suggests daily aspirin could result in a net benefit for some people without established CVD, further muddying the debate over whether aspirin is an effective preventive tool for those without heart disease.

The FDA announced Sept. 13 it identified low levels of N-nitrosodimethylamine, or NDMA, in popular heartburn drugs including Zantac.

Contrary to a recent FDA advisory that acknowledged a late mortality signal with paclitaxel-coated and -eluting devices, a study published in the Journal of Endovascular Therapy found such stents safe in the long-term for treating femoropopliteal lesions in people with peripheral artery disease.

Men who struggle with erectile dysfunction—especially more severe cases—are at an increased risk of CHD, total heart disease, stroke and all-cause mortality, according to research published in the Journal of Sexual Medicine.

The FDA issued a warning letter to e-cigarette giant Juul early this week accusing the company of illegally promoting its vaping products as safer than cigarettes.

Investigators from the New York State Department of Health believe they’ve identified the culprit behind the recent onslaught of vaping-related illnesses in the U.S., Health Exec reports.

Men who live on their own—but not women—struggle to take warfarin as directed, according to research presented Sept. 2 at the ESC Congress in Paris.

Malpractice litigation is a risk that’s inherent to acute stroke care, Mount Sinai researchers reported in Stroke this month—and while just over half of cases get resolved, the remainder can cost medical centers millions in payouts.

Heart disease deaths are on the rise in the U.S., according to research published in the Journal of the American Medical Association Aug. 27—and they have been for almost a decade.

It takes somewhere between 10 and 15 years—and possibly up to 25—after quitting tobacco for former heavy smokers’ CVD risk to revert to pre-smoking levels, according to a study published August 20 in JAMA.